Business
PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that Dr. Frank Bedu-Addo, Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023 being held August 7-8, 2023. Details for the event are as follows: BTIG Virtual Biotechnology Conference 2023Presentation Date: Tuesday, August 8, 2023Event: Fireside chat Time: 11:30 AM EDT For more information about the conference or to schedule one-on-one meetings, please contact your BTIG representative directly. About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS0301, and Infectimune® T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and will be advancing into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in 2023. Our Infectimune® based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. Investor Relations:Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: [email protected] Rich CockrellCG CapitalPhone: +1 (404) 736-3838Email: [email protected] Media Contacts:Tiberend Strategic Advisors, Inc.Dave SchemeliaPhone: +1 (609) [email protected] Eric ReissPhone: +1 (802) 249-1136ereiss@ti...